Therapy Response and Survival among Patients with Gynecologic Tumors Treated with Transarterial Chemoperfusion and Transarterial Chemoembolization

Thomas J. Vogl, Andreea I Nica, A I Nica, Christian Booz, Leona S. Alizadeh, Sven Becker, İbrahim Yel, Teodora Biciusca, Aynur Gökduman, Mirela Dimitrova, Christian Wolfram, Tatjana Gruber‐Rouh, John Bielfeldt, Hamzah Adwan
Medicina (Kaunas, Lithuania) · 2024 · vol. 60(10) , pp. 1585 · doi:10.3390/medicina60101585 · PMID:39459373 · PMC11509747 · W4402925380
Other OA: gold CC0
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-13 ⓘ

This study evaluated transarterial chemoperfusion and chemoembolization in unresectable gynecologic tumors, finding a stable disease rate of 67% and median overall survival of 16.15 months.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Background and Objectives: This study aimed to evaluate the tumor response relating to and survival benefit of transarterial chemoperfusion (TACP) and transarterial chemoembolization (TACE) in the treatment of patients with unresectable gynecologic tumors who are intolerant of or have a suboptimal response to chemotherapy and radiotherapy. Materials and Methods: Between January 2000 and October 2023, 75 patients diagnosed with gynecologic tumors underwent 213 TACP and 154 TACE procedures. Of these, 33 patients were treated with TACP, 20 were treated with TACE, and 22 received a combination of both therapies. A retrospective evaluation of local tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST) was conducted, and survival rates were determined using the Kaplan-Meier estimator. Results: Of the total 75 patients, 50 (67%) maintained a stable course of disease until the completion of therapy, 10 (13%) had a partial response, 2 (3%) had a complete response following thermal ablation, and 13 (17%) experienced progression. Furthermore, a 6% reduction in the sum of the longest diameters and an 8% reduction in tumor volume were observed. The median overall survival was 16.15 months, while the median progression-free survival was 13.19 months. Conclusions: TACP and TACE are potential treatment options for local tumor control in patients with unresectable gynecologic tumors who are intolerant of or show a poor response to chemotherapy and radiotherapy. However, further investigation and adjustment of treatment protocols are required to improve therapy response and survival outcomes.

My notes (saved in your browser only)

MeSH descriptors

Chemoembolization, Therapeutic Chemoembolization, Therapeutic Chemoembolization, Therapeutic Genital Neoplasms, Female Genital Neoplasms, Female Genital Neoplasms, Female Adult Aged Aged, 80 and over Female Humans Kaplan-Meier Estimate Middle Aged Retrospective Studies Treatment Outcome

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

References (25)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:46:21.925728+00:00
License: CC0 · commercial use OK